Obesity Clinical Trial
Official title:
Measurement of Kidney Function Indexed Extracellular Volume Before and After Obesity Surgery in Kidney Patients With Severe Obesity or Massive
Obesity promotes chronic kidney disease and is accelerating its shift to the stage of renal
replacement. Bariatric surgery is a treatment for severe or morbid obesity whose renal
benefit is currently unknown. The glomerular filtration rate (GFR) is the best parameter to
define the kidney function. It can be estimated using formulas by assaying endogenous
markers (creatinine, cystatin C) or measured with an exogenous tracer glomerular filtration
(51 Cr-EDTA).
Bariatric surgery alters the production of endogenous markers and the extracellular volume
(VEC) with 2 important consequences on the assessment of GFR: the formula to estimate GFR is
not possible to compare renal function before and after surgery because of the variation in
production of endogenous glomerular filtration markers in the same subject; decreasing VEC
predicted decreased GFR after surgery, since these parameters are in part proportional to
each other.
Our working hypothesis is that bariatric surgery protects the kidneys of patients with
chronic kidney disease. To demonstrate this, investigators propose to compare the ratio DFG
/ VEC before and after gastric bypass.
Goals The main objective is to measure the effect of gastric bypass on the report DFG / VEC.
Secondary objectives are to assess the effect of gastric bypass on the albumin / urine
creatinine and evaluate the performance of the main GFR estimating formulas in people with
severe or morbid obesity.
| Status | Recruiting |
| Enrollment | 14 |
| Est. completion date | December 2016 |
| Est. primary completion date | July 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Topic GFR estimated by having the simplified formula of MDRD <60 ml / min / 1.73 m² - Topic with BMI = 40 kg / m², or = 35 kg / m² - Subject having at least one comorbidity could be improved after surgery after failure of medical treatment: hypertension , OSAHS and other severe respiratory disorders, severe metabolic disorders, particularly type 2 diabetes , debilitating musculoskeletal diseases, steatohepatitis nonalcoholic . - Topic who signed the informed consent - Topic affiliated to the social security - Male or female Topics - Elderly 18 to 70 inclusive Exclusion Criteria: - Non- Caucasian person because the necessary correction factors and not always available for the formula to estimate GFR ( Cockcroft , Salazar and Corcoran ) . - No major under guardianship - Nobody hospitalized without his consent and not protected by law - Private person of liberty - Pregnant Woman, knowing that a pregnancy test will be performed for women of childbearing age . Results will be communicated to the patient by a doctor of his choice. - Rapidly progressive glomerulonephritis - Nephrotic proteinuria ranking |
Intervention Model: Single Group Assignment, Masking: Open Label
| Country | Name | City | State |
|---|---|---|---|
| France | CHU de Nice | Nice |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Universitaire de Nice |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Ratio DFG / VEC | Average ratio DFG / VEC before and one year after gastric bypass | Month 12 | No |
| Secondary | Albumin / urine creatinine | Month 12 | No | |
| Secondary | GFR estimation formula | GFR using the Cockcroft formulas , Salazar and Corcoran , simplified MDRD and CKD -EPI . Each of GFR estimation formula , we calculate the mean bias by the difference between the estimated value and the measured value and the percentage of patients with the value obtained by estimation is between -25 % and + 25 % in value measured ( awerage Within 50 or AW50 ) | Month 12 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |